2021
DOI: 10.1016/j.oraloncology.2021.105256
|View full text |Cite
|
Sign up to set email alerts
|

MICA A5.1 homozygous genotype is associated with a risk for early-onset oral cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 22 publications
0
3
0
Order By: Relevance
“…We recently reported that OSCC patients with the MICA A5.1 allele have a higher survival rate than those with other alleles as a result of the NKG2D receptor-mediated activation of NK cell signaling. Additionally, we demonstrated that the prognosis for patients with the A5.1 homozygous genotype was significantly better than that for patients with the other MICA genotypes [ 19 ]. Consequently, genetic polymorphisms of MICA and CD45RO + /TILs may serve as potential prognostic factors for OSCC patients.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…We recently reported that OSCC patients with the MICA A5.1 allele have a higher survival rate than those with other alleles as a result of the NKG2D receptor-mediated activation of NK cell signaling. Additionally, we demonstrated that the prognosis for patients with the A5.1 homozygous genotype was significantly better than that for patients with the other MICA genotypes [ 19 ]. Consequently, genetic polymorphisms of MICA and CD45RO + /TILs may serve as potential prognostic factors for OSCC patients.…”
Section: Discussionmentioning
confidence: 99%
“…Paraffin-embedded tissues were cut at 4–6 μm thickness and immuno-stained to evaluate the expression of CD3, CD8, CD45RO, Granzyme B, and MICA in every OSCC sample [ 19 ]. Subsequently, the sections were exposed to protein block 5% normal horse serum (Thermo Fisher Scientific, Waltham, MA, USA) and 2% normal goat serum (Thermo Fisher Scientific) and incubated overnight at 4°C with mouse monoclonal anti-MICA (Nichirei Biosciences, Inc., Tokyo, Japan), mouse monoclonal anti-CD3 (PS1, Nichirei Biosciences, Inc.), mouse monoclonal anti-CD8 (C8/144B, Nichirei Biosciences, Inc.), mouse monoclonal anti-UCHL (UCHL1, Nichirei Biosciences, Inc.) for CD45RO, and mouse monoclonal anti-Granzyme B (GrB-7, Nichirei Biosciences, Inc.), respectively [ 20 , 21 ].…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation